This interview with a Germany-based key opinion leader (KOL) provides insights into the evolving disease landscape for hereditary angioedema (HAE). The discussion includes the prescribing of on-demand treatments and long-term prophylaxis options, including the recently approved products Dawnzera (donidalorsen), an RNA-targeted medicine designed to target plasma prekallikrein from Ionis Pharmaceuticals, Ekterly (sebetralstat), a plasma kallikrein inhibitor from KalVista Pharmaceuticals and Andembry (garadacimab), a monoclonal antibody inhibiting factor XIIa. The KOL also provides views on pipeline drug candidates, including Pharvaris’s orally bioavailable small-molecule bradykinin B2 receptor antagonist deucrictibant, BioCryst Pharmaceuticals’ monoclonal antibody inhibitor of plasma kallikrein navenibart and Intellia Therapeutics’ in vivo CRISPR gene editing candidate lonvoguran ziclumeran.

This interview was conducted on June 26, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.